Partner With Us
Patented Antibody Immobilization System
CaptSure™ is TGR’s patented antibody immobilization system which replaces other types of binding molecules, such as streptavidin/biotin with the added benefit of multiplexing.
CaptSure™ technology is composed of the following:
• a CaptSure™ tag.
• a proprietary monoclonal CaptSure™ antibody that binds with high affinity and specificity to the CaptSure™ tag.
The CaptSure™ antibody is immobilized to a surface such as a bead or assay plate and the CaptSure™ tag is covalently linked to a primary assay antibody. This novel approach enables an infinite number of sandwich immunoassays to be built on a generic platform by simply introducing different target specific antibody content.
CaptSure™ Technology
The CaptSure™ technology was originally licensed by Abcam in 2012 to develop their very successful SimpleStep ELISA assay range (> 1400 assays and growing).
More recently, the CaptSure™ technology has been licensed by Western Australian diagnostics company, Proteomics International for the development and commercialization of their Promarker™ D diagnostic ELISA for diabetic kidney disease.